Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular foundations for personalized therapy in prostate cancer.
Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. Fisher KW, et al. Among authors: scarpelli m. Curr Drug Targets. 2015;16(2):103-14. doi: 10.2174/1389450115666141229154500. Curr Drug Targets. 2015. PMID: 25547910 Review.
Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Lopez-Beltran A, et al. Among authors: scarpelli m. Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756. Curr Drug Targets. 2015. PMID: 25654736 Review.
Present and future of personalized medicine in adult genitourinary tumors.
Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. Ciccarese C, et al. Among authors: scarpelli m. Future Oncol. 2015;11(9):1381-8. doi: 10.2217/fon.15.30. Future Oncol. 2015. PMID: 25952784 Review.
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: scarpelli m. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Metabolic Alterations in Renal and Prostate Cancer.
Ciccarese C, Santoni M, Massari F, Modena A, Piva F, Conti A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora G, Montironi R. Ciccarese C, et al. Among authors: scarpelli m. Curr Drug Metab. 2016;17(2):150-5. doi: 10.2174/1389200216666151015112356. Curr Drug Metab. 2016. PMID: 26467063 Review.
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
512 results